ClinicalTrials.gg
CompletedNCT02284243Updated May 2, 2017Results posted

Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy Surgery

A Phase 2 interventional study of Intranasal Dexmedetomidine and Intranasal Placebo in Pain, Post-operative, sponsored by Baudax Bio. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-05-02.

Sponsored by Baudax Bio · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 136 studies testing dexmedetomidine in Pain, Postoperative — 35 open to participants now, 38 under way, 5 of them phase 3. Dexmedetomidine · Pain, Postoperative.

Enrollment
16th of 136
168 · median 85
Started
2014
with 6 others
Phase 2
10 of 136
2 open now
Registered
9th of 136
by date
Lead sponsor
2 of 136
Baudax Bio

Among the 136 studies testing dexmedetomidine in Pain, Postoperative, this one is the 16th largest by enrollment, is one of 7 that started in 2014, is one of 10 in phase 2, and was the 9th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

35 of the 136 studies testing dexmedetomidine in Pain, Postoperative are open now, in 9 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies testing dexmedetomidine in Pain, Postoperative, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the analgesic efficacy, on Post-Operative Day (POD) 1, of DEX-IN compared with placebo, using the summed pain intensity difference over the first 48 hours (SPID48) in subjects with acute moderate to severe pain following unilateral bunionectomy.

03

Conditions studied

  • Pain, Post-operative

Keywords

  • Bunion
  • Bunionectomy
  • Pain
  • Analgesia
  • dexmedetomidine
  • intranasal
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily provide written .
  • Male or female between 18 and 70 years of age, inclusive.
  • Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair
  • Be American Society of Anesthesiology (ASA) physical class 1 or 2.
  • Female subject are eligible only if all the following apply:

    • Not pregnant;
    • Not lactating;
    • Not planning to become pregnant during the study;
    • Be surgically sterile; or at least two year post menopausal; or have a monogamous partner who is surgically sterile; or is practicing double-barrier ; or practicing abstinence; or using an insertable, injectable, transdermal, or combination oral contraceptive.
  • Male subjects must be surgically sterile or commit to the use of a reliable method of birth control
  • Have a ≤35 kg/m2
  • Be able to understand the study procedures, comply with all study procedures, and agree to participate in the study program.

Exclusion criteria

Exclusion Criteria:

  • Have a known allergy to dexmedetomidine or any in DEX-IN/placebo or to any peri- or postoperative medications used in this study.
  • Have a abnormal clinical laboratory test value.
  • Have history of or positive test results for , or or C.
  • Have a history or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, or other condition that would preclude participation in the study.
  • Have a history of migraine or frequent headaches, seizures, or are currently taking anticonvulsants.
  • Have another painful physical condition that may confound the assessments of post operative pain.
  • Have a history of syncope or other syncopal attacks.
  • Have evidence of a clinically significant 12 lead abnormality.
  • Have a history of alcohol abuse (regularly drinks > 4 units of alcohol per day; 8 oz. beer, 3 oz. wine, 1 oz. spirits) or prescription/illicit drug abuse..
  • Have positive results on the urine drug screen or alcohol breath test indicative of illicit drug or alcohol abuse.
  • Have a history or evidence of orthostatic hypotension.
  • Have a resting heart rate of \<50 beats per minutes or systolic blood pressure \<100mmHg.
  • Have been receiving or have received chronic opioid therapy defined as greater than 15 morphine equivalents units per day for greater than 3 out of 7 days per week over a one-month period within 12 months.
  • Use concurrent therapy that could interfere with the evaluation of efficacy or safety, such as any drugs which in the investigator's opinion may exert significant analgesic properties or act synergistically with DEX-IN.
  • Unable to discontinue medications, that have not been at a stable dose for at least 14 days prior to the scheduled bunionectomy procedure, within 5 half lives of the specific prior medication (or, if half life is not known, within 48 hours) before dosing.
  • Have utilized any intranasal medications within the preceding 10 days.
  • Have signs or a history of significant rhinitis or rhinorrhea (constant or chronic), nasal polyps, mucosal lesions of the nostril, postnasal drip of any etiology (constant or chronic), nasal ulcers, septal perforation or deviation, any nasal surgery, anosmia, nasal piercings, or frequent nosebleeds or other nasal pathology, that is sufficient to interfere with IN drug delivery.
  • Have had an upper respiratory tract infection within 14 days of screening.
  • Have utilized , either systemically, inhalational either intranasally or oral, or by intra-articular injection, within 14 days prior to the study.
  • Have received any product within 30 days before dosing with study medication.
  • Have previously received DEX-IN in clinical trials, or had bunionectomy in the last 3 months.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    DEX-IN 50mcg

    DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.

    Drug: Intranasal Dexmedetomidine

  • Placebo comparator
    IN Placebo

    IN Placebo every 6 hours for 48 hours.

    Drug: Intranasal Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Summed Pain Intensity Difference Over the First 48 Hours (SPID48).

    Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.

    Time frame: 48 hours

Secondary outcomes

  1. SPID at Various Other Time Points

    Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.

    Time frame: Up to 48 Hours

  2. Time to Perceptible and Meaningful Pain Relief

    Kaplan-Meier analysis of time to perceptible and meaningful pain relief for 50th percentile of subjects. Time to perceptible pain relief and time to meaningful pain relief were measured using the double-stopwatch method. The first stopwatch was given to each subject with the instructions to stop the watch when they first perceive pain relief to occur (time to perceptible relief). Once the first watch was stopped, the second stopwatch was given to the subject with the instructions to stop the watch when they are first experiencing meaningful pain relief (time to meaningful relief). A shorter time to pain relief is better.

    Time frame: 6 hours

  3. Number of Subjects With Significant Pain Improvement Following the First Study Dose.

    Time frame: 6 hours

  4. Use of Rescue Medication (Oral Opioids)

    Number of subjects requiring rescue medication (Oral opioids) within 48 hours after first study dose

    Time frame: 48 hours

  5. Time to First Rescue Medication Use

    Kaplan Meier analysis of time to first use of rescue analgesia 50th percentile of subjects. Rescue analgesia (oral oxycodone) was available to subjects with inadequately controlled pain. All doses of rescue analgesia administered were recorded and the time from the first study dose to first rescue analgesia in each subject was evaluated. A longer time to first rescue is better.

    Time frame: 48 hours

  6. Number of Subjects With Complete Protection From PONV

    Time frame: 24 hours

07

Results

Posted May 2, 2017

Participant flow

Participant flow — Overall Study
MilestoneDEX-IN 50mcgIN Placebo
Started8484
Completed8081
Not completed43
Withdrew: Lack of efficacy33
Withdrew: Adverse event10

Outcome measures

PrimarySummed Pain Intensity Difference Over the First 48 Hours (SPID48).

Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.

Time frame:
48 hours
Reported as:
Mean · units on a scale
Summed Pain Intensity Difference Over the First 48 Hours (SPID48).
units on a scaleDEX-IN 50mcgIN Placebo
Summed Pain Intensity Difference Over the First 48 Hours (SPID48).-2328.2 ± 5746.724-548.90 ± 5819.373
Statistical analysis
  • DEX-IN 50mcg vs IN Placebo · ANCOVA · p = 0.0180
SecondarySPID at Various Other Time Points

Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.

Time frame:
Up to 48 Hours
Reported as:
Mean · units on a scale
SPID at Various Other Time Points
units on a scaleDEX-IN 50mcgIN Placebo
SPID 0-6-346.57 ± 579.0378-120.46 ± 590.7313
SPID 0-12-568.89 ± 1213.410-151.93 ± 1263.656
SPID 0-24-1043.2 ± 2553.890-239.07 ± 2717.394
Statistical analysis
  • DEX-IN 50mcg vs IN Placebo · ANCOVA · p = <0.05 (Applies to SPID 0-6, SPID 0-12, and SPID 0-24)
SecondaryTime to Perceptible and Meaningful Pain Relief

Kaplan-Meier analysis of time to perceptible and meaningful pain relief for 50th percentile of subjects. Time to perceptible pain relief and time to meaningful pain relief were measured using the double-stopwatch method. The first stopwatch was given to each subject with the instructions to stop the watch when they first perceive pain relief to occur (time to perceptible relief). Once the first watch was stopped, the second stopwatch was given to the subject with the instructions to stop the watch when they are first experiencing meaningful pain relief (time to meaningful relief). A shorter time to pain relief is better.

Time frame:
6 hours
Reported as:
Median · minutes
Time to Perceptible and Meaningful Pain Relief
minutesDEX-IN 50mcgIN Placebo
Time to perceptible pain relief18.39 (15.50 to 25.68)33.0 (18.18 to 85.33)
Time to meaningful pain relief79.32 (55.25 to 151.88)NA (NA to NA)
Statistical analysis
  • DEX-IN 50mcg vs IN Placebo · Log Rank · p = <0.05 (Applies to perceptible and meaningful pain relief)
SecondaryNumber of Subjects With Significant Pain Improvement Following the First Study Dose.
Time frame:
6 hours
Reported as:
Number · participants
Number of Subjects With Significant Pain Improvement Following the First Study Dose.
participantsDEX-IN 50mcgIN Placebo
≥30% reduction in pain2615
≥50% reduction in pain92
Statistical analysis
  • DEX-IN 50mcg vs IN Placebo · Cochran-Mantel-Haenszel · p = <0.05 (Applies to ≥30% and ≥50% reduction in pain)Test for general association stratified by site
SecondaryUse of Rescue Medication (Oral Opioids)

Number of subjects requiring rescue medication (Oral opioids) within 48 hours after first study dose

Time frame:
48 hours
Reported as:
Number · participants
Use of Rescue Medication (Oral Opioids)
participantsDEX-IN 50mcgIN Placebo
Use of Rescue Medication (Oral Opioids)6676
SecondaryTime to First Rescue Medication Use

Kaplan Meier analysis of time to first use of rescue analgesia 50th percentile of subjects. Rescue analgesia (oral oxycodone) was available to subjects with inadequately controlled pain. All doses of rescue analgesia administered were recorded and the time from the first study dose to first rescue analgesia in each subject was evaluated. A longer time to first rescue is better.

Time frame:
48 hours
Reported as:
Median · hours
Time to First Rescue Medication Use
hoursDEX-IN 50mcgIN Placebo
Time to First Rescue Medication Use4.94 (4.03 to 7.85)2.68 (1.42 to 3.47)
Statistical analysis
  • DEX-IN 50mcg vs IN Placebo · Log Rank · p = 0.0009
SecondaryNumber of Subjects With Complete Protection From PONV
Time frame:
24 hours
Reported as:
Number · participants
Number of Subjects With Complete Protection From PONV
participantsDEX-IN 50mcgIN Placebo
Number of Subjects With Complete Protection From PONV7270
Statistical analysis
  • DEX-IN 50mcg vs IN Placebo · Cochran-Mantel-Haenszel · p = 0.7718

Adverse events

Collected over All AEs were collected through the Day 7 study visit. All SAEs were assessed through the Day 7 visit, but were reported through 30 days of the last study visit if the investigator was made aware of the event.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DEX-IN 50mcg—1/84 (1.2%)51/84 (60.7%)
IN Placebo—0/84 (0%)36/84 (42.9%)
Most frequent serious events
Most frequent serious events
EventDEX-IN 50mcgIN Placebo
HypotensionVascular disorders1/840/84
Most frequent other events
Showing 10 of 17
Most frequent other events
EventDEX-IN 50mcgIN Placebo
Blood Pressure DecreasedInvestigations22/843/84
NauseaGastrointestinal disorders13/8414/84
Nasal DiscomfortRespiratory, thoracic and mediastinal disorders7/842/84
VomitingGastrointestinal disorders4/846/84
HeadacheNervous system disorders6/844/84
Nasal CongestionRespiratory, thoracic and mediastinal disorders4/841/84
Nasal DrynessRespiratory, thoracic and mediastinal disorders4/843/84
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/844/84
BradycardiaCardiac disorders3/840/84
DizzinessNervous system disorders3/841/84

Baseline characteristics

Safety analysis set - All subjects receiving at least one study dose

Age, Categorical
Age, Categorical(Participants)DEX-IN 50mcgIN PlaceboTotal
<=18 years000
Between 18 and 65 years8281163
>=65 years235
Age, Continuous
Age, Continuous(years)DEX-IN 50mcgIN PlaceboTotal
Mean43.9 ± 12.3744.0 ± 13.0844.0 ± 12.69
Sex: Female, Male
Sex: Female, Male(Participants)DEX-IN 50mcgIN PlaceboTotal
Female7975154
Male5914
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DEX-IN 50mcgIN PlaceboTotal
Hispanic or Latino333972
Not Hispanic or Latino514596
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DEX-IN 50mcgIN PlaceboTotal
American Indian or Alaska Native033
Asian448
Native Hawaiian or Other Pacific Islander000
Black or African American202141
White5956115
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)DEX-IN 50mcgIN PlaceboTotal
United States8484168
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)DEX-IN 50mcgIN PlaceboTotal
Mean26.6 ± 4.3127.4 ± 4.0827.0 ± 4.20
Baseline pain intensity score (NPRS)
Baseline pain intensity score (NPRS)(units on a scale)DEX-IN 50mcgIN PlaceboTotal
Mean6.4 ± 1.426.7 ± 1.906.5 ± 1.68
08

Study locations

3 sites
  • Trovare Clinical Research, Inc.
    Bakersfield, California, United States
  • Lotus Clinical Research, LLC
    Pasadena, California, United States
  • Endeavor Clinical Trials, P.A.
    San Antonio, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2014
First posted
Nov 5, 2014
Start
Oct 2014
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results first posted
May 2, 2017
Last update
May 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02284243
Lead sponsor
Baudax Bio
Collaborators
Lotus Clinical Research, LLC
Responsible party
Sponsor
First posted
Nov 5, 2014
Start date
Oct 2014
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
May 2, 2017
Last update
May 2, 2017

Study contacts

Neil Singla, MD
principal investigator · Lotus Clinical Research, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion